SITRYX THERAPEUTICS LIMITED

10366466
Active Oxford

Research and experimental development on biotechnology

49 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
S

SITRYX THERAPEUTICS LIMITED

10366466

Research and experimental development on biotechnology

Founded 8 Sept 2016 Active Oxford, United Kingdom 49 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 23 Feb 2026 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 12 Sept 2025 Next due 21 Sept 2026 2 months remaining
Net assets £19M £4M 2025 year on year
Total assets £22M £18M 2025 year on year
Total Liabilities £3M £13M 2025 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

101 Bellhouse Building Magdalen Centre The Oxford Science Park Oxford OX4 4GA

Website

www.example.com

Full company profile for SITRYX THERAPEUTICS LIMITED (10366466), an active life sciences and medical technology company based in Oxford, United Kingdom. Incorporated 8 Sept 2016. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type group
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Balance Sheet & P&L (2017–2025)

Cash in Bank

£15.33M

Decreased by £18.97M (-55%)

Net Assets

£19.03M

Decreased by £4.37M (-19%)

Total Liabilities

£3.30M

Decreased by £13.50M (-80%)

Turnover

£3.01M

Employees

49

Increased by 4 (+9%)

Debt Ratio

15%

Decreased by 27 (-64%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 4

Investors (7)

Investor NameInvestor SinceParticipating Rounds
Investor 4Jan 2018Series A, Seed, Series B
Investor 2Oct 2018Series A, Series B
Investor 3Oct 2018Series A, Series B

Share Capital

Share Capital

Share allotments and capital structure

1 Allotment 371,389 Shares £37.139 Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
30 May 2025371,389£37.139£0

Officers

Officers

1 active 2 resigned
Status
Paul-peter TakDirectorDutchEngland6623 Jan 2018Active

Shareholders

Shareholders (44)

Eli Lilly And Company
17.7%
8,024,263
Sofinnova Capital Viii Fpci
17.6%
7,992,352

Persons with Significant Control

Persons with Significant Control (0)

0 Active 1 Ceased

Professor Houman Ashrafian

Ceased 23 Jan 2018

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

1 satisfied

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
10 Jun 2026IncorporationMemorandum Articles
10 Jun 2026IncorporationMemorandum Articles
30 Mar 2026OfficersAppointment of Dr Jeremy Griggs as director on 24 Mar 2026
30 Mar 2026OfficersTermination of Garrett Rhyasen as director on 10 Mar 2026
10 Mar 2026ResolutionResolutions
10 Jun 2026 Incorporation

Memorandum Articles

10 Jun 2026 Incorporation

Memorandum Articles

30 Mar 2026 Officers

Appointment of Dr Jeremy Griggs as director on 24 Mar 2026

30 Mar 2026 Officers

Termination of Garrett Rhyasen as director on 10 Mar 2026

10 Mar 2026 Resolution

Resolutions

Recent Activity

Latest Activity

Memorandum Articles

3 weeks ago on 10 Jun 2026

Memorandum Articles

3 weeks ago on 10 Jun 2026

Appointment of Dr Jeremy Griggs as director on 24 Mar 2026

3 months ago on 30 Mar 2026

Termination of Garrett Rhyasen as director on 10 Mar 2026

3 months ago on 30 Mar 2026

Resolutions

3 months ago on 10 Mar 2026